Top

Published in:

13-05-2023 | Breast Cancer | Research Article

Cancer in pathologically confirmed multiple system atrophy

Authors: William P. Cheshire, Shunsuke Koga, Philip W. Tipton, Hiroaki Sekiya, Owen A. Ross, Ryan J. Uitti, Keith A. Josephs, Dennis W. Dickson

Published in: Clinical Autonomic Research | Issue 4/2023

Abstract

Purpose

The aim of this study was to assess whether cancer occurs with increased frequency in multiple system atrophy (MSA). The pathological hallmark of MSA is glial cytoplasmic inclusions containing aggregated α-synuclein, and the related protein γ-synuclein correlates with invasive cancer. We investigated whether these two disorders are associated clinically.

Methods

Medical records of 320 patients with pathologically confirmed MSA seen between 1998 and 2022 were reviewed. After excluding those with insufficient medical histories, the remaining 269 and an equal number of controls matched for age and sex were queried for personal and family histories of cancer recorded on standardized questionnaires and in clinical histories. Additionally, age-adjusted rates of breast cancer were compared with US population incidence data.

Results

Of 269 cases in each group, 37 with MSA versus 45 of controls had a personal history of cancer. Reported cases of cancer in parents were 97 versus 104 and in siblings 31 versus 44 for MSA and controls, respectively. Of 134 female cases in each group, 14 MSA versus 10 controls had a personal history of breast cancer. The age-adjusted rate of breast cancer in MSA was 0.83%, as compared with 0.67% in controls and 2.0% in the US population. All comparisons were nonsignificant.

Conclusion

The evidence from this retrospective cohort found no significant clinical association of MSA with breast cancer or other cancers. These results do not exclude the possibility that knowledge about synuclein pathology at the molecular level in cancer may lead to future discoveries and potential therapeutic targets for MSA.

Wenning GK, Stankovic I, Vignatelli L et al. (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37(6):1131–1148. https://doi.org/10.1002/mds.29005CrossRefPubMedPubMedCentral

Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33(6):615–20. https://doi.org/10.1111/j.1365-2990.2007.00907.xCrossRefPubMed

Dickson DW, Liu W, Hardy J et al. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 155(4):1241–1251. https://doi.org/10.1016/s0002-9440(10)65226-1CrossRefPubMedPubMedCentral

Uversky VN, Li J, Souillac P et al. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 277(14):11970–11978. https://doi.org/10.1074/jbc.M109541200CrossRefPubMed

Miller KM, Mercado NM, Sortwell CE (2021) Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor [published online April 12, 2001]. NPJ Parkinson’s Dis 7(1):35. https://doi.org/10.1038/s41531-021-00179-6CrossRef

Kim WS, Kågedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases [published online October 27, 2014]. Alzheimers Res Ther 6(5):73. https://doi.org/10.1186/s13195-014-0073-2CrossRefPubMedPubMedCentral

Sugier PE, Lucotte EA, Domenighetti C et al. (2023) Comprehensive unbiased risk factor assessment for genetics and environment in Parkinson’s disease (Courage-PD) consortium; Truong T ,Elbaz A. Investigation of shared genetic risk factors between Parkinson’s disease and cancers. Mov Disord. https://doi.org/10.1002/mds.29337CrossRefPubMed

Zhang X, Guarin D, Mohammadzadehhonarvar N, Chen X, Gao X (2021) Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants. BMJ Open 11(7):e046329. https://doi.org/10.1136/bmjopen-2020-046329. (Erratum in: BMJ Open. 2021 Sep 22;11(9):e046329corr1)CrossRefPubMedPubMedCentral

Mencke P, Hanss Z, Boussaad I et al. (2020) Bidirectional relation between Parkinson’s disease and glioblastoma multiforme. Front Neurol 11:898. https://doi.org/10.3389/fneur.2020.00898CrossRefPubMedPubMedCentral

10.

Filippou PS, Outeiro TF (2021) Cancer and Parkinson’s disease: common targets, emerging hopes. Mov Disord 36(2):340–346. https://doi.org/10.1002/mds.28425CrossRefPubMed

11.

Vanacore N (2005) Epidemiological evidence on multiple system atrophy. J Neural Transm (Vienna) 112(12):1605–1612. https://doi.org/10.1007/s00702-005-0380-7CrossRefPubMed

12.

Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K (2007) Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German competence network on Parkinson’s disease. J Neural Transm (Vienna) 114(9):1161–1165. https://doi.org/10.1007/s00702-007-0746-0CrossRefPubMed

13.

Seo JH, Yong SW, Song SK, Lee JE, Sohn YH, Lee PH (2010) A case-control study of multiple system atrophy in Korean patients. Mov Disord 25(12):1953–1959. https://doi.org/10.1002/mds.23185CrossRefPubMed

14.

Köllensperger M, Geser F, Ndayisaba JP, EMSA-SG et al. (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25(15):2604–2612. https://doi.org/10.1002/mds.23192CrossRefPubMed

15.

Nozaki I, Kato-Motozaki Y, Ikeda T et al. (2014) Clinical features in association with neurodegenerative diseases and malignancies. Eur Neurol 71(3–4):99–105. https://doi.org/10.1159/000353995CrossRefPubMed

16.

Surguchov A (2008) Molecular and cellular biology of synucleins. Int Rev Cell Mol Biol 270:225–317. https://doi.org/10.1016/S1937-6448(08)01406-8CrossRefPubMed

17.

Carnazza KE, Komer LE, Xie YX et al. (2022) Synaptic vesicle binding of α-synuclein is modulated by β- and γ-synucleins. Cell Rep 39(2):110675. https://doi.org/10.1016/j.celrep.2022.110675CrossRefPubMedPubMedCentral

18.

Zheng Y, Cai H, Zhao J, Yu Z, Feng T (2022) Alpha-synuclein species in oral mucosa as potential biomarkers for multiple system atrophy. Front Aging Neurosci 14:1010064. https://doi.org/10.3389/fnagi.2022.1010064CrossRefPubMedPubMedCentral

19.

Kim JY, Illigens BM, McCormick MP, Wang N, Gibbons CH (2019) Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol 15(2):135–142. https://doi.org/10.3988/jcn.2019.15.2.135CrossRefPubMedPubMedCentral

20.

Kanda T, Tsukagoshi H, Oda M, Miyamoto K, Tanabe H (1996) Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson’s disease and multiple system atrophy. Acta Neuropathol 91(2):145–154. https://doi.org/10.1007/s004010050406CrossRefPubMed

21.

Rong Z, Shen F, Wang Y et al. (2021) Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson’s disease from multiple system atrophy and progressive supranuclear paralysis [published online May 19, 2021]. Neurosci Lett 756:135964. https://doi.org/10.1016/j.neulet.2021.135964CrossRefPubMed

22.

Barba L, Paolini Paoletti F, Bellomo G et al. (2022) Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers. Mov Disord 37(4):669–683. https://doi.org/10.1002/mds.28941CrossRefPubMedPubMedCentral

23.

Hayashi J, Carver JA (2022) β-synuclein: an enigmatic protein with diverse functionality [published online January 16, 2022]. Biomolecules 12(1):142. https://doi.org/10.3390/biom12010142CrossRefPubMedPubMedCentral

24.

Surguchov A, Palazzo RE, Surgucheva I (2001) Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskelet 49(4):218–228. https://doi.org/10.1002/cm.1035CrossRef

25.

Sanjeev A, Mattaparthi VSK (2019) Computational study on the role of γ-synuclein in inhibiting the α-synuclein aggregation. Cent Nerv Syst Agents Med Chem 19(1):24–30. https://doi.org/10.2174/1871524918666181012160439CrossRefPubMed

26.

Surgucheva I, Sharov VS, Surguchov A (2012) γ-Synuclein: seeding of α-synuclein aggregation and transmission between cells. Biochemistry 51(23):4743–4754. https://doi.org/10.1021/bi300478wCrossRefPubMed

27.

He K, Wang P (2015) Unregulated long non-coding RNA-AK058003 promotes the proliferation, invasion and metastasis of breast cancer by regulating the expression levels of the γ-synuclein gene. Exp Ther Med 9(5):1727–1732. https://doi.org/10.3892/etm.2015.2323CrossRefPubMedPubMedCentral

28.

Tian L, Zhao Y, Truong MJ, Lagadec C, Bourette RP (2018) Synuclein gamma expression enhances radiation resistance of breast cancer cells. Oncotarget 9(44):27435–27447. https://doi.org/10.18632/oncotarget.25415CrossRefPubMedPubMedCentral

29.

Ji H, Liu YE, Jia T et al. (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 57(4):759–764PubMed

30.

Guo J, Shou C, Meng L et al. (2007) Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer 121(6):1296–1305. https://doi.org/10.1002/ijc.22763CrossRefPubMed

31.

Wu K, Huang S, Zhu M et al. (2013) Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer [published online May 22, 2013]. Med Oncol 30(3):612. https://doi.org/10.1007/s12032-013-0612-xCrossRefPubMed

32.

Hsu CC, Su YF, Tsai KY et al. (2020) Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy [published online July 10, 2020]. Cancer Cell Int 20:300. https://doi.org/10.1186/s12935-020-01401-w. (Erratum in: Cancer Cell Int 2020 Aug 26;20:410)CrossRefPubMedPubMedCentral

33.

Fei J, Xiao C, Yang M, Zhou X, Gong P (2021) Inhibition of SNCG suppresses the proliferation of lung cancer cells induced by high glucose [published online December 14, 2020]. Mol Med Rep 23(2):138. https://doi.org/10.3892/mmr.2020.11777CrossRefPubMed

34.

Wang K, Shen Y, Xu J et al. (2020) Evaluation of synuclein-γ levels by novel monoclonal antibody in saliva and cancer tissues from oral squamous cell carcinoma patients. Neoplasma 67(3):707–713. https://doi.org/10.4149/neo_2020_190619N523CrossRefPubMed

35.

Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK (2000) Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88(9):2154–2163CrossRefPubMed

36.

Hu H, Sun L, Guo C et al. (2009) Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res 15(17):5485–5493. https://doi.org/10.1158/1078-0432.CCR-08-2491CrossRefPubMed

37.

Hibi T, Mori T, Fukuma M et al. (2009) Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer [published online April 7, 2009]. Clin Cancer Res 15(8):2864–2871. https://doi.org/10.1158/1078-0432.CCR-08-2946CrossRefPubMed

38.

Jellinger KA, Wenning GK, Stefanova N (2021) Is multiple system atrophy a prion-like disorder? [Published online September 18, 2021]. Int J Mol Sci 22(18):10093. https://doi.org/10.3390/ijms221810093CrossRefPubMedPubMedCentral

39.

Miki Y, Foti SC, Asi YT et al. (2019) Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 142(9):2813–2827. https://doi.org/10.1093/brain/awz189CrossRefPubMed

40.

Koga S, Aoki N, Uitti RJ et al. (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85(5):404–412. https://doi.org/10.1212/WNL.0000000000001807CrossRefPubMedPubMedCentral

41.

American Cancer Society. Lifetime risk of developing and dying from cancer, 2016–2018. https://www.cancer.org/content/dam/CRC/PDF/Public/509.00.pdf. Accessed 28 Feb 2023

42.

National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov. Accessed 28 Feb 2023

43.

Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791–1800. https://doi.org/10.1212/wnl.58.12.1791CrossRefPubMed

44.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259. https://doi.org/10.1007/BF00308809CrossRefPubMed

45.

Montine TJ, Phelps CH, Beach TG, National Institute on Aging; Alzheimer’s Association et al. (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123(1):1–11. https://doi.org/10.1007/s00401-011-0910-3CrossRefPubMed

46.

Dogra A, Kumar J (2023) Biosynthesis of anticancer phytochemical compounds and their chemistry. Front Pharmacol 14:1136779. https://doi.org/10.3389/fphar.2023.1136779CrossRefPubMedPubMedCentral

47.

Al-Yousef N, Shinwari Z, Al-Shahrani B, Al-Showimi M, Al-Moghrabi N (2020) Curcumin induces re expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncol Rep 43(3):827–838. https://doi.org/10.3892/or.2020.7473CrossRefPubMedPubMedCentral

48.

Xu B, Chen J, Liu Y (2022) Curcumin interacts with α-synuclein condensates to inhibit amyloid aggregation under phase separation. ACS Omega 7(34):30281–30290. https://doi.org/10.1021/acsomega.2c03534CrossRefPubMedPubMedCentral

49.

Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 39(10):1119–25. https://doi.org/10.1080/10715760500233113CrossRefPubMed

50.

El Nebrisi E, Javed H, Ojha SK, Oz M, Shehab S (2020) Neuroprotective effect of curcumin on the nigrostriatal pathway in a 6-hydroxydopmine-induced rat model of Parkinson’s disease is mediated by α7-nicotinic receptors. Int J Mol Sci 21(19):7329. https://doi.org/10.3390/ijms21197329CrossRefPubMedPubMedCentral

51.

Nebrisi EE (2021) Neuroprotective activities of curcumin in Parkinson’s disease: a review of the literature. Int J Mol Sci 22(20):11248. https://doi.org/10.3390/ijms222011248CrossRefPubMedPubMedCentral

52.

Kim TE, Newman AJ, Imberdis T et al. (2021) Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity. Hum Mol Genet 30(23):2332–2346. https://doi.org/10.1093/hmg/ddab188CrossRefPubMedPubMedCentral

53.

Galvin JE, Uryu K, Lee VM, Trojanowski JQ (1999) Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA 96(23):13450–13455. https://doi.org/10.1073/pnas.96.23.13450CrossRefPubMedPubMedCentral

54.

Carnazza KE, Komer LE, Xie YX, Pineda A, Briano JA, Gao V, Na Y, Ramlall T, Buchman VL, Eliezer D, Sharma M, Burré J (2022) Synaptic vesicle binding of α-synuclein is modulated by β- and γ-synucleins. Cell Rep 39(2):110675. https://doi.org/10.1016/j.celrep.2022.110675CrossRefPubMedPubMedCentral

55.

Surgucheva I, Newell KL, Burns J, Surguchov A (2014) New α- and γ-synuclein immunopathological lesions in human brain [published online September 11, 2014]. Acta Neuropathol Commun 2:132. https://doi.org/10.1186/s40478-014-0132-8CrossRefPubMedPubMedCentral

56.

Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ (1999) The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 160(2):515–522. https://doi.org/10.1006/exnr.1999.7228CrossRefPubMed

57.

Nishioka K, Wider C, Vilariño-Güell C et al. (2010) Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol 67(8):970–5. https://doi.org/10.1001/archneurol.2010.177CrossRefPubMedPubMedCentral

58.

Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18(10):1779–1794. https://doi.org/10.1093/hmg/ddp090CrossRefPubMedPubMedCentral

59.

Min L, Zhang C, Ma R, Li X, Yuan H, Li Y, Chen R, Liu C, Guo J, Qu L, Shou C (2016) Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients. BMC Cancer 16(1):717CrossRefPubMedPubMedCentral

60.

Lee SH, Kim YS, Han W et al. (2016) Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography [published online September 16, 2016]. Medicine (Baltimore) 95(37):e4874. https://doi.org/10.1097/MD.0000000000004874CrossRefPubMed

61.

Nakashima K, Uematsu T, Takahashi K et al. (2019) Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer 26(2):206–214. https://doi.org/10.1007/s12282-018-0914-0CrossRefPubMed

62.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Autonomic Disorders Consortium et al. (2017) Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol 81(2):287–297. https://doi.org/10.1002/ana.24877CrossRefPubMedPubMedCentral

63.

Xia C, Postuma RB (2020) Diagnosing multiple system atrophy at the prodromal stage. Clin Auton Res 30(3):197–205. https://doi.org/10.1007/s10286-020-00682-5CrossRefPubMed

64.

McKay JH, Cheshire WP (2018) First symptoms in multiple system atrophy. Clin Auton Res 28(2):215–221. https://doi.org/10.1007/s10286-017-0500-0CrossRefPubMedPubMedCentral

65.

Sakakibara R, Sekiguchi Y, Panicker NJ et al. (2022) Female urinary retention progressing to possible multiple system atrophy-cerebellar form after 12 years. Intern Med. https://doi.org/10.2169/internalmedicine.8724-21CrossRefPubMedPubMedCentral

Title: Cancer in pathologically confirmed multiple system atrophy
Authors: William P. Cheshire
Shunsuke Koga
Philip W. Tipton
Hiroaki Sekiya
Owen A. Ross
Ryan J. Uitti
Keith A. Josephs
Dennis W. Dickson
Publication date: 13-05-2023
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Published in: Clinical Autonomic Research / Issue 4/2023
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-023-00946-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cancer in pathologically confirmed multiple system atrophy

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Exploring the prevalence of undetected bradyarrhythmia in dementia with Lewy bodies

A tale of two syndromes: nontraumatic Frey’s syndrome in a woman with Sjögren’s syndrome

A case showing how hyperventilation may decrease blood pressure in neurogenic orthostatic hypotension

Exaggerated blood pressure response to standing in young-to-middle-age subjects: prevalence and factors involved

Associations between physical activity and autonomic function during deep breathing test: the Swedish CArdioPulmonary bioImage Study (SCAPIS)

Early-onset hereditary isolated non-neurogenic orthostatic hypotension in a Swedish family